The role of biologically active substances in gastroesophageal reflux disease in patients with type 2 diabetes mellitus
Background. The factors influencing the progression and clinical manifestations of gastroesophageal reflux disease (GERD) in patients with type 2 diabetes mellitus (DM) have not been sufficiently studied so far. To investigate the features of changes in serum prostaglandin (Pg) І2 and F2α levels depending on the clinical course of GERD in patients with type 2 DM was the purpose of our work. Materials and methods. The study involved 82 patients with GERD and type 2 DM (main, group 1) and comparison group (85 individuals, group 2). Serum levels of prostaglandin PgF2α and 6-keto-prostaglandin F1α (blood prostacyclin — PgI2) were evaluated in patients. Results. Digestive complaints characteristic of GERD have been detected in 61.0 % of persons from group 1, 22.0 % of individuals with combined pathology have been diagnosed with otolaryngologic form of GERD, and 17.1 % had a cardiac form. Patients with combined pathology have a more significant increase in the concentration of PgI2 with extra-esophageal manifestations of GERD, especially with its otolaryngologic form (4.1 times higher than indicators of the control group), whereas in patients with cardiac mask of GERD, its concentration is increased 3.5-fold, and in those with esophageal manifestations of GERD and type 2 DM — 3-fold. In patients with GERD, similar changes were detected 2.4 times (otolaryngologic manifestations), 2.2 times (cardiac manifestations) and 1.6 times (typical manifestations of GERD) more often. Conclusions. GERD in patients with type 2 DM is often manifested by extravascular symptoms (otolaryngologic, cardiac form). The maximum increase in the level of serum prostacyclin is established in patients with extraesophageal manifestations of GERD and type 2 DM, especially with its otolaryngologic form.
Full Text:PDF (Українська)
Sviridova TN, Alekseev NJu, Kozlov JuS, authors; Minakov JeV, editor. Gastrojezofageal'naja refljuksnaja bolezn': metodicheskie ukazanija [Gastroesophageal reflux disease: guidelines]. Voronezh; 2009. 69 p. (in Russian).
Promberger R, Lenglinger J, Riedl O, et al. Gastro-oesophageal reflux disease in type 2 diabetics: symptom load and pathophysiologic aspects - a retro-pro study. BMC Gastroenterol. 2013 Aug 23;13:132. doi: 10.1186/1471-230X-13-132.
Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal reflux disease in type II diabetes mellitus with or without peripheral neuropathy. J Neurogastroenterol Motil. 2011 Jul;17(3):274-8. doi: 10.5056/jnm.2011.17.3.274.
Robleto DO, Herman CA. Cardiovascular effects of prostaglandin I2 and prostaglandin F2 alpha in the unanesthetized bullfrog, Rana catesbeiana. J Exp Zool. 1988 Apr;246(1):10-6. doi: 10.1002/jez.1402460103.
Burduli NM, Tadtaeva DIa. The influence of intravenous laser therapy on prostaglandin E2 and F2-alpha dynamics and the state of microcirculation in the patients presenting with gastroesophageal reflux disease. Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul'tury. 2012; 89(6):17–20. (in Russian).
- There are currently no refbacks.
Copyright (c) 2018 GASTROENTEROLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018